Рибоциклиб + гормонотерапия в адъювантном режиме при раннем раке молочной железы: профилактика рецидивов. Новые возможности

Огнерубов Н. А. Рибоциклиб + гормонотерапия в адъювантном режиме при раннем раке молочной железы: профилактика рецидивов. Новые возможности. Современная Онкология. 2023;25(4):432–439.
DOI: 10.26442/18151434.2023.4.202548

© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.

________________________________________________

Ognerubov NA. Ribociclib + adjuvant hormone therapy in early breast cancer: prevention of recurrence. New opportunities. A review. Journal of Modern Oncology. 2023;25(4):432–439.
DOI: 10.26442/18151434.2023.4.202548

Читать PDF

Аннотация

Рак молочной железы (РМЖ) занимает лидирующее положение среди всех злокачественных новообразований у женщин во всем мире и 4‑е место по смертности. Большинство случаев диагностируют на I–III стадиях. Среди молекулярно-биологических вариантов преобладает люминальный HER2 отрицательный (HER2-), составляющий 70–75%. В настоящее время методы лечения, сочетающие хирургическое вмешательство с химио- и, несколько реже, лучевой терапией, с последующей адъювантной гормонотерапией на протяжении до 10 лет, являются стандартной опцией при РМЖ. Реализация стандарта преследует профилактику раннего рецидива у пациентов в группе высокого риска с первично гормонорезистентной опухолью. Тем не менее по окончании лечения он развивается у 27–57% больных РМЖ II–III стадий. Для их профилактики при раннем HR положительном (HR+) HER2- РМЖ применяют инновационный класс лекарственных препаратов – ингибиторы циклинзависимых киназ 4/6 – в комбинации с гормонотерапией (ингибиторы ароматазы, антиэстрогены, агонисты гонадотропин-рилизинг-гормона), чему и посвящено рандомизированное исследование III фазы NATALEE, оценивающее эффективность и безопасность рибоциклиба в сочетании с эндокринной терапией при раннем неметастатическом РМЖ. В нем принимали участие больные РМЖ II–III стадий, в том числе с N0. Пациентам исследовательской группы назначали рибоциклиб в дозе 400 мг/сут в течение 21 дня в комбинации с ингибиторами ароматазы, а в контроле – только ингибиторы ароматазы. Медиана наблюдения – 34 мес. Трехлетняя выживаемость без инвазивного заболевания составила в группе рибоциклиба 90,7%, у лиц контроля – 87,6%. Риск отдаленного метастазирования и инвазивных заболеваний снижался на 25,1% в группе рибоциклиба. Соответственно, рибоциклиб продемонстрировал тенденцию к улучшению общей выживаемости. Начальная доза 400 мг/сут позволила снизить частоту нежелательных явлений, среди которых преобладают нейтропения (62,5%), артралгия (37,3%) и печеночная токсичность (26,4%). Самыми частыми причинами досрочного прекращения приема рибоциклиба стали печеночная токсичность (8,9%) и артралгия (1,3%). Полученные результаты демонстрируют статистически и клинически превосходящую эффективность применения рибоциклиба в комбинации с гормонотерапией при лечении раннего HR+ HER2- РМЖ с высоким риском развития рецидива.

Ключевые слова: ранний рак молочной железы, рецидив, профилактика, ингибиторы CDK4/6, рибоциклиб, ингибиторы ароматазы

________________________________________________

Breast cancer (BC) occupies a leading position among all malignant neoplasms in women worldwide and is the 4th deadliest. Most cases are diagnosed in stages I–III. Among the molecular biological variants, luminal HER2 negative (HER2-) prevails, accounting for 70–75%. Currently, therapies combining surgery with chemotherapy and, more rarely, radiation therapy, followed by adjuvant hormone therapy for up to 10 years, are a standard of care in BC. The goal of these regimens is the prevention of early recurrence in patients in the high-risk group with a primary hormone-resistant tumor. However, at the end of treatment, it occurs in 27–57% of patients with stage II–III breast cancer. For its prevention in early HR-positive (HR+) HER2- BC, an innovative class of drugs, cyclin-dependent kinase 4/6 inhibitors, is used combined with hormone therapy (aromatase inhibitors, anti-estrogens, gonadotropin-releasing hormone agonists), which is the subject of a randomized phase III NATALEE study evaluating the efficacy and safety of ribociclib in combination with endocrine therapy in early non-metastatic BC. The study enrolled patients with stage II–III breast cancer, including those with N0. Patients of the study group received ribociclib at a dose of 400 mg/day for 21 days in combination with aromatase inhibitors, and in the control group, only aromatase inhibitors. The median follow-up was 34 months. Three-year survival without invasive disease was 90.7% in the ribociclib group and 87.6% in controls. The risk of distant metastasis and invasive diseases was reduced by 25.1% in the ribociclib group. Therefore, ribociclib tended to improve overall survival. The initial dose of 400 mg/day reduced the incidence of adverse events; the most common were neutropenia (62.5%), arthralgia (37.3%) and hepatic toxicity (26.4%). The most common reasons for discontinuing ribociclib were hepatic toxicity (8.9%) and arthralgia (1.3%). The results demonstrate a statistical and clinical superiority of ribociclib in combination with hormone therapy in the treatment of early HR+ HER2- breast cancer with a high risk of recurrence.

Keywords: early breast cancer, relapse, prevention, CDK4/6 inhibitors, ribociclib, aromatase inhibitors

Полный текст

Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Globocan cancer observatory. 2020. Available at: https://gco.iarc.fr. Accessed: 09.09.2023.
2. Dafni U, Tsourti Z, Alatsathianos I. Breast Cancer Statistics in the European Union: Incidence and Survival across European Countries. Breast Care (Basel). 2019;14(6):344‑53. DOI:10.1159/000503219
3. Burstein HJ, Curigliano G, Thürlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32(10):1216‑35. DOI:10.1016/j.annonc.2021.06.023
4. Gomis RR, Gawrzak S. Tumor cell dormancy. Mol Oncol. 2017;11(1):62‑78. DOI:10.1016/j.molonc.2016.09.009
5. National Comprehensive Cancer Network. Breast Cancer. Available at: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed: 17.06.2022.
6. National Comprehensive Cancer Network. Breast Cancer (version 4.2020). Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf Google Scholar. Accessed: 17.06.2022.
7. Jakesz R, Greil R, Gnant M, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst. 2007;99(24):1845‑53. DOI:10.1093/jnci/djm246
8. Howell A. Adjuvant aromatase inhibitors for breast cancer. Lancet. 2005;366(9484):431‑3. DOI:10.1016/S0140‑6736(05)67036‑5
9. Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol. 2018;29(8):1634‑57. DOI:10.1093/annonc/mdy192
10. Sledge GW Jr, Toi M, Neven P, et al. The effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed On Endocrine Therapy – MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. 2020;6(1):116‑24. DOI:10.1001/jamaoncol.2019.4782
11. Slamon DJ, Neven P, Chia S, et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA‑3. J Clin Oncol. 2018;36(24):2465‑72. DOI:10.1200/JCO.2018.78.9909
12. Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:5. DOI:10.1038/s41523‑018‑0097‑z
13. Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA‑7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904‑15. DOI:10.1016/S1470‑2045(18)30292‑4
14. Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clin Cancer Res. 2017;23:5218‑24. DOI:10.1158/1078‑0432.CCR‑17‑0754
15. Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017;35:2875‑84. DOI:10.1200/JCO.2017.73.7585
16. Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35(32):3638‑46. DOI:10.1200/JCO.2017.75.6155
17. O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016;13(7):417‑30. DOI:10.1038/nrclinonc.2016.26
18. Santo L, Siu KT, Raje N. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers. Semin Oncol. 2015;42(6):788‑800. DOI:10.1053/j.seminoncol.2015.09.024
19. Klein ME, Kovatcheva M, Davis LE, et al. CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. Cancer Cell. 2018;34(1):9‑20. DOI:10.1016/j.ccell.2018.03.023
20. Lange CA, Yee D. Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. Endocr Relat Cancer. 2011;18(4):19‑24. DOI:10.1530/ERC‑11‑0112
21. Li H, Zheng B. Overexpression of the Ubiquitin-Specific Peptidase 9 X–Linked (USP9X) Gene is Associated with Upregulation of Cyclin D1 (CCND1) and Downregulation of Cyclin-Dependent Inhibitor Kinase 1A (CDKN1A) in Breast Cancer Tissue and Cell Lines. Med Sci Monit. 2019;25:4207‑16. DOI:10.12659/MSM.914742
22. Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer. 2002;2(12):910‑7. DOI:10.1038/nrc950
23. Ding L, Cao J, Lin W, et al. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer. Int J Mol Sci. 2020;21(6):1960. DOI:10.3390/ijms21061960
24. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646‑74. DOI:10.1016/j.cell.2011.02.013
25. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153‑66. DOI:10.1038/nrc2602
26. Laurenti E, Frelin C, Xie S, et al. CDK6 levels regulate quiescence exit in human hematopoietic stem cells. Cell Stem Cell. 2015;16(3):302‑13. DOI:10.1016/j.stem.2015.01.017
27. Chen P, Lee NV, Hu W, et al. Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance. Mol Cancer Ther. 2016;15(10):2273‑81. DOI:10.1158/1535‑7163.MCT‑16‑0300
28. Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;375(20):1925‑36. DOI:10.1056/NEJMoa1607303
29. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016;375(18):1738‑48. DOI:10.1056/NEJMoa1609709
30. Turner NC, Slamon DJ, Ro J, et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2018;379(20):1926‑36. DOI:10.1056/NEJMoa1810527
31. Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2020;382(6):514‑24. DOI:10.1056/NEJMoa1911149
32. Braal CL, Jongbloed EM, Wilting SM, et al. Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. Drugs. 2021;81(3):317‑31. DOI:10.1007/s40265‑020‑01461‑2
33. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med. 2022;386(10):942‑50. DOI:10.1056/NEJMoa2114663
34. Finn R, Rugo H, Dieras V, et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor-positive/human epidermal growth factor receptor 2‑negative advanced breast cancer (ER+/HER2– ABC): Analyses from PALOMA‑2. J Clin Oncol. 2022;40(17_suppl.):LBA1003.
35. Goetz M. MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy in patients with HR+, HER2- advanced breast cancer. Presented at SABCS 2023 (December 06). GS01‑12. Abstract 1643629. Available at: http://www.sabcs.org. Accessed: 13.09.2023.
36. Lu YS, Im SA, Colleoni M, et al. Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA‑7: A Phase III Randomized Clinical Trial. Clin Cancer Res. 2022;28(5):851-9. DOI:10.1158/1078‑0432.CCR‑21‑3032
37. Yardley DA, Yap YS, Azim HA, et al. 205P Pooled exploratory analysis of survival in patients (pts) with HR+/HER2- advanced breast cancer (ABC) and visceral metastases (mets) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) trials. Ann Oncol. 2022;33(Suppl. 7):S629. DOI:10.1016/j.annonc.2022.07.239
38. Iqbal J, Ginsburg O, Rochon PA, et al. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015;313(2):165‑73. DOI:10.1001/jama.2014.17322
39. Pan H, Gray R, Braybrooke J, et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med. 2017;377(19):1836‑46. DOI:10.1056/NEJMoa1701830
40. Gnant M, Dueck AC, Frantal S, et al. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG‑42/AFT‑05/BIG‑14‑03). J Clin Oncol. 2022;40(3):282‑93. DOI:10.1200/JCO.21.02554
41. Johnston SRD, Toi M, O’Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2‑negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(1):77‑90. DOI:10.1016/S1470‑2045(22)00694‑5
42. Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol. 2020;38(34):3987‑98. DOI:10.1200/JCO.20.02514
43. Eli Lilly and Company release. Landmark 5-Year monarchE Outcome Data Demonstrate Verzenio® (abemaciclib)’s Long-Term Impact on Cancer Recurrence in High-Risk Early Breast Cancer. October 20, 2023. Available at: https://investor.lilly.com/news-releases/news-release-details/landmark‑5‑year-monarche-outcome-dat.... Accessed: 20.09.2023.
44. Harbeck N, Rastogi P, Martin M, et al. Adjuvant Abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki‑67 analysis from the monarchE study the monarchE study. Ann Oncol. 2021;32(12):1571‑81. DOI:10.1016/j.annonc.2021.09.015
45. Harbeck N, Rastogi P, O’Shaughnessy J, et al. Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5‑year efficacy outcomes. Ann Oncol. 2023;34(S2):S1255-S56. DOI:10.1016/j.annonc.2023.10.007
46. Rugo HS, O’Shaughnessy J, Boyle F, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. Ann Oncol. 2022;33(6):616‑27. DOI:10.1016/j.annonc.2022.03.006
47. Hamilton EP, Kim JH, Eigeliene N, et al. Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC). J Clin Oncol. 2023;41(16_suppl.):501. DOI:10.1200/JCO.2023.41.16_suppl.501
48. Mayer EL, Dueck AC, Martin M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021;22(2):212‑22. DOI:10.1016/S1470‑2045(20)30642‑2
49. Kim S, Tiedt R, Loo A, et al. The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models. Oncotarget. 2018;9(81):35226‑40. DOI:10.18632/oncotarget.26215
50. Spring LM, Scarpetti L, Niemierko A, et al. Phase II study of adjuvant endocrine therapy with CDK4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER, part 1). Canc Res. 2022;82(4_Suppl.):P1‑14‑02-P1‑14‑02. DOI:10.1158/1538‑7445.sabcs21‑p1‑14‑02
51. Spring L, Griffin C, Isakoff SJ, et al. Phase II study of adjuvant endocrine therapy with CDK4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER). J Clin Oncol. 2020;38(15_suppl.):531. DOI:10.1200/JCO.2020.38.15_suppl.531
52. Peuker CA, Yaghobramzi S, Grunert C, et al. Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial. Eur J Cancer. 2022;162:45‑55. DOI:10.1016/j.ejca.2021.11.025
53. Rao P, Tullai J, Aspesi P, et al. Characterization of cancer cell lines made senescent by exposure to ribociclib, doxorubicin, or TGFβ1, and identification of genes required for entry into senescence and sensecent cell survival. In: AACR Annual Meeting. 10‑15 April and 17‑21 May. 2021.
54. Riggio AI, Varley KE, Welm AL. The lingering mysteries of metastatic recurrence in breast cancer. Br J Cancer. 2021;124(1):13‑26. DOI:10.1038/s41416‑020‑01161‑4
55. Tripathy D, S-a IM, Colleoni M, et al. Updated overall survival (OS) results from the phase III MONALEESA‑7 trial of pre- and perimenopausal patients with HR+/HER2- advanced breast cancer (ABC) treated with endocrine therapy (ET) +/- ribociclib. San Antonio Breast Cancer Symposium, San Antionio, TX, 8‑11, 2020.
56. Hortobagyi G. Ribociclib + Nonsteroidal Aromatase Inhibitor as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer: Final Invasive Disease – Free Survival Analysis From the NATALEE Trial. Presented at SABCS 2023. GS03‑03. Available at: http://www.sabcs.org. Accessed: 12.12.2023.
57. Diéras V, Harbeck N, Joy AA, et al. Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‑2 Trial. Oncologist. 2019;24(12):1514‑25. DOI:10.1634/theoncologist.2019‑0019
58. Slamon D, Stroyakovskiy D, Yardley D, et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial. J Clin Oncol. 2023;41(17_suppl.):LBA500. DOI:10.1200/JCO.2023.41.17_suppl.LBA500
59. Burris HA, Chan A, Bardia A, et al. Safety and impact of dose reductions on efficacy in the randomised MONALEESA‑2, -3 and -7 trials in hormone receptor-positive, HER2‑negative advanced breast cancer. Br J Cancer. 2021;125(5):679‑86. DOI:10.1038/s41416‑021‑01415‑9

________________________________________________

Авторы

Н. А. Огнерубов*

Пензенский институт усовершенствования врачей – филиал ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Пенза, Россия
*ognerubov_n.a@mail.ru

________________________________________________

Nikolai A. Ognerubov*

Penza Institute for Advanced Training of Physicians – branch of the Russian Medical Academy of Continuous Professional Education, Penza, Russia
*ognerubov_n.a@mail.ru

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.